Amgen Inc. (AMGN)

Oncology Corporate Profile

Stock Performance

161.0000
-1.8500

HQ Location

One Amgen Center Drive
Thousand Oaks, CA 91320

Company Description

Amgen is a biotechnology company that engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. It markets human therapeutic products in the areas of supportive cancer care, nephrology, inflammation, and oncology.

Website: http://www.amgen.com

Brand Generic Indication
Aranesp®darbepoetin alfaAranesp® is indicated for the treatment of anemia:
• associated with chronic renal failure, including patients on dialysis and patients not on dialysis.
• in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. Aranesp® use has not been demonstrated in controlled clinical trials to improve symptoms of anemia, quality of life, fatigue, or patient well-being. Aranesp® is not indicated for use in patients receiving hormonal agents, therapeutic biologic products, or radiotherapy unless receiving concomitant myelosuppressive chemotherapy.
Blincyto®blinatumomabBlincyto® is the first BiTE® antibody construct and the first single-agent immunotherapy to be approved by the U.S. Food and Drug Administration (FDA).3 BLINCYTO was granted breakthrough therapy and priority review designations by the FDA, and is now approved in the U.S. for the treatment of Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Kepivance®paliferminKepivance® is indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support. The safety and efficacy of Kepivance® have not been established in patients with non-hematologic malignancies.
Neulasta®pegfilgrastimNeulasta® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Neupogen®filgrastimNeupogen® is indicated to decrease the incidence of infection' as manifested by febrile neutropenia' in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever. Neupogen® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML. Neupogen® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae' eg' febrile neutropenia' in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation. Neupogen® is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Neupogen® is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg' fever' infections' oropharyngeal ulcers) in symptomatic patients with congenital neutropenia' cyclic neutropenia' or idiopathic neutropenia.
Nplate®romiplostimNplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.
Vectibix®panitumumabVectibix® is indicated as a single agent for the treatment of EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. The effectiveness of Vectibix® as a single agent for the treatment of EGFR-expressing, metastatic colorectal carcinoma is based on progression-free survival. Currently no data are available that demonstrate an improvement in disease-related symptoms or increased survival with Vectibix®.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
motesanib diphosphate / AMG 706VEGFR1-3, PDGFR, c-Kit inhibitor (oral)1st line metastatic Non Small Cell Lung Cancer (NSCLC)IIIMillennium
AMG 386 (+ paclitaxel)Fc-peptide fusion protein targeting angiopoietins (peptibody)2nd line metastatic Ovarian cancerIII
ABP 980(trastuzumab biosimilarBreast cancerIII
ABP 494bevacizumab biosimilarColorectal cancerIIIAllergan
rilotumumab / AMG 102anti-hepatocyte growth factor/scatter factor (HGF/SF) monoclonal antibodyGastric cancerIII
ABP 215bevacizumab biosimilarNon Small Cell Lung Cancer (NSCLC)IIIAllergan
Trebananibpeptibody inhibitorOvarian cancerIII
Kyprolis® / carfilzomibproteasome inhibitorRefractory multiple MyelomaIII
Vectibix® / panitumumabanti-EGFR monoclonal antibody (humanized)1st line metastatic Colorectal cancerIII
Vectibix® / panitumumabanti-EGFR monoclonal antibody (humanized)1st line metastatic Head & Neck cancerIII
Vectibix® / panitumumabanti-EGFR monoclonal antibody (humanized)2nd line metastatic Colorectal cancerIII
Vectibix® / panitumumabanti-EGFR monoclonal antibody (humanized)2nd line metastatic Head & Neck cancerIII
Xgeva® / denosumab / AMG 162anti-RANKL antibodyBone loss in Breast cancerIII
Xgeva® / denosumab / AMG 162anti-RANKL antibodyMultiple MyelomaIII
Xgeva® / denosumab / AMG 162anti-RANKL antibodyPrevention of bone metastases in Breast cancerIII
motesanib diphosphate / AMG 706VEGFR1-3, PDGFR, c-Kit inhibitor (oral)1st line metastatic Breast cancerIIMillennium
ganitumab / AMG 479insulin-like growth factor-1 receptor (IGF-1R) inhibitor (monoclonal antibody)Breast cancerII
adecatumumab / MT201anti-EpCAM monoclonal antibodyColorectal cancerIIEMD Serono
ganitumab / AMG 479insulin-like growth factor-1 receptor (IGF-1R) inhibitor (monoclonal antibody)Ewing's SarcomaII
AMG 386Fc-peptide fusion protein targeting angiopoietins (peptibody)Hepatocellular carcinoma (HCC)II
AMG 386Fc-peptide fusion protein targeting angiopoietins (peptibody)Neo-adjuvant Breast cancerII
conatumumab / AMG 655pro-apoptotic TRAIL receptor-2 agonistNeo-adjuvant Breast cancerII
ganitumab / AMG 479insulin-like growth factor-1 receptor (IGF-1R) inhibitor (monoclonal antibody)Small Cell Lung Cancer (SCLC)II
Blincyto® / blinatumomabanti-CD19 monoclonal antibody (surface antigen specific for B cells)2nd line metastatic Acute Lymphocytic Leukemia (ALL)II
Nplate® / romiplostimthrombopoietin agonistChemotherapy-induced thrombocytopenia in LymphomaII
Nplate® / romiplostimthrombopoietin agonistChemotherapy-induced thrombocytopenia in NSCLCII
Nplate® / romiplostimthrombopoietin agonistMyelodysplastic Syndrome (MDS)II
Vectibix® / panitumumabanti-EGFR monoclonal antibody (humanized)Locally advanced Head & Neck cancerII
adecatumumab (+ docetaxel) / MT201anti-EpCAM monoclonal antibody1st line metastatic Breast cancerIEMD Serono
dulanermin / rhApo2L/TRAILdeath receptors DR4 and DR5 inhibitor1st line metastatic Colorectal cancerIGenentech / Roche
MEDI-565 (MT111)CEA BiTE antibody1st line metastatic Colorectal cancerIMedImmune
AMG 330anti-BCMA x anti-CD3 bispecific antibodyAcute Myelogenous Leukemia (AML)I
AMG 595anti-EGFRvIII antibody drug conjugateGlioblastoma Multiforme (GBM)I
AMG 595tubulin inhibitorGliomaI
AMG 420anti-BCMA x anti-CD3 bispecific antibodyMultiple MyelomaI
oprozomiboral proteasome inhibitorMultiple MyelomaI
AMG 224antibody drug conjugateMultiple MyelomaI
rilotumumab / AMG 102anti-hepatocyte growth factor/scatter factor (HGF/SF) monoclonal antibodyNon Small Cell Lung Cancer (NSCLC)I
dulanermin / rhApo2L/TRAILdeath receptors DR4 and DR5 inhibitorNon-Hodgkin's Lymphoma (NHL)IGenentech / Roche
AMG 319pi3k kinase inhibitorVarious cancer typesI
AMG 176small moleculeVarious cancer typesI
AMG 211anti-BCMA x anti-CD3 bispecific antibodyVarious cancer typesIMedImmune
AMG 820IgG2 c-fms antagonistic antibody (humanized)Various cancer typesI
MT293 (D93/TRC093)IgG1 monoclonal antibodyVarious cancer typesITRACON Pharmaceuticals
AMG 900aurora kinases A, B, and C inhibitorVarious cancer typesI
AMG 208c-Met inhibitorVarious cancer typesI
AMG 337c-Met kinase inhibitorVarious cancer typesI
dulanermin / rhApo2L/TRAILdeath receptors DR4 and DR5 inhibitorVarious cancer typesIGenentech / Roche
MT110EpCAM (CD326) antibodyVarious cancer typesI
rilotumumab / AMG 102anti-hepatocyte growth factor/scatter factor (HGF/SF) monoclonal antibodyVarious cancer typesI
AMG 780anti-angiopoietin antibodyVarious cancer typesI
Imlygic® / talimogene laherparepveconcolytic immunotherapy (derived from HSV-1)MelanomaI
Kyprolis® / carfilzomibproteasome inhibitorMultiple MyelomaI
Kyprolis® / carfilzomibproteasome inhibitorSmall Cell Lung Cancer (SCLC)I
MT228 (MORAb-028)IgM monoclonal antibody (humanized)1st line metastatic MelanomaPreclinicalMorphotek
MT110EpCAM (CD326) antibodyVarious cancer typesPreclinicalMedImmune

View additional information on product candidates here »

Source: http://www.amgen.com

Recent News Headlines

Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients

10/21/2016 07:03 am

(TheStreet) Oct 20, 2016 - Study met primary endpoint of non-inferiority versus zoledronic acid in delaying bone complications known as skeletal-related events.

New Amgen Data In Melanoma And Metastatic Colorectal Cancer To Be Presented At The European Society For Medical Oncology 2016 Congress

10/6/2016 11:18 am

(Amgen) Oct 5, 2016 - Interim data from Phase 2 trial provides further insight into Imlygic® (talimogene laherparepvec) as a potential combination partner with a checkpoint inhibitor for patients with advanced melanoma: retrospective analyses of key studies evaluating Vectibix® (panitumumab) combination regimen in first- and second-line metastatic colorectal cancer evaluate impact of tumor site of origin on treatment efficacy.

NICE Rejects Lilly's Portrazza, but Backs Bayer's Xofigo and Amgen's Imlygic

9/30/2016 11:41 am

(PharmaTimes [UK]) Sept 30, 2016 - Patients with lung cancer will not be able to access Eli Lilly's Portrazza on the National Health Service in England and Wales, after a final rejection from the National Institute for Health and Care Excellence.

Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study

9/29/2016 11:20 am

(Yahoo! Finance) Sept 28, 2016 - Amgen today announced positive top-line results for erenumab (AMG 334) from a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention (ARISE).

Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients

9/27/2016 10:41 am

(Amgen) Sept 27, 2016 - Amgen today announced top-line results of the Phase 3 CLARION trial, which evaluated an investigational regimen of KYPROLIS® (carfilzomib), melphalan and prednisone (KMP) versus Velcade® (bortezomib), melphalan and prednisone (VMP) for 54 weeks in patients with newly diagnosed multiple myeloma who were ineligible for hematopoietic stem-cell transplant.

Amgen's Multiple Myeloma Drug Falls Short In New-Patient Study

9/27/2016 10:34 am

(Reuters) Sept 27, 2016 - Amgen Inc said on Tuesday its multiple myeloma drug, Kyprolis, did not fare better than Takeda Pharmaceutical Co Ltd's older therapy Velcade in a study involving patients who had not yet been treated for the disease.

Dr Reddy's Inks Pact With Us-Based Amgen To Market Three Drugs In India

9/16/2016 11:10 am

(Firstpost/Press Trust India [Hyderabad, India]) Sept 16, 2016 - Dr Reddy's Laboratories has expanded its strategic collaboration with US-based independent biotechnology firm Amgen to market and distribute in India three of latter's medicines, used in the therapy areas of oncology and osteoporosis.

Amgen Obtains Global Development And Commercial Rights From Boehringer Ingelheim For Investigational BiTE® Immuno-Oncology Drug For Multiple Myeloma

9/1/2016 11:13 am

(Amgen) Sept 1, 2016 - Amgen and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager (BiTE®) that targets B-cell maturation antigen (BCMA), a potential target for multiple myeloma.

Novartis Wins Federal OK For Biosimilar Version Of Amgen’s Enbrel

8/31/2016 11:16 am

(Boston Globe/Associated Press) Aug 31, 2016 - US regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.

Amgen's Shameful Silence Covers Up Reasons for FDA Drug Rejection

8/25/2016 11:45 am

(TheStreet) Aug 25, 2016 - An Amgen drug to treat secondary hyperparathyroidism was rejected by U.S. regulators Wednesday but the biotech company offered no public explanation for why the drug's marketing application was denied.

Amgen, Sanofi Cholesterol Drugs Not Cost-Effective, Study Says

8/17/2016 11:26 am

(Bloomberg) Aug 16, 2016 - Amgen Inc., Sanofi and Regeneron Pharmaceuticals Inc. would need to cut prices on their new cholesterol-lowering drugs by more than two-thirds to make them cost-effective to use in the U.S., a study found.

In Change Of Tack, UK Agency Backs Amgen Virus-Based Cancer Drug

8/9/2016 11:15 am

(Reuters) Aug 9, 2016 - Britain's cost-effectiveness agency NICE has recommended use of a virus-based melanoma drug from Amgen, reversing an earlier negative decision after the company provided further information.

AbbVie Files Patent Suit Over Amgen’s Copy of Humira

8/8/2016 11:27 am

(NASDAQ/Dow Jones Business News) Aug 5, 2016 - Drugmaker AbbVie Inc. has filed a patent-infringement lawsuit against rival Amgen Inc. seeking to halt looming sales of a lower-priced replica of AbbVie's top-selling drug, Humira.

Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration

8/2/2016 08:41 am

(Amgen) Aug 2, 2016 - Amgen and Advaxis, Inc. today announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor.

Amgen, Allergan Biosimilar Found as Effective as Roche Cancer Drug

7/21/2016 10:42 am

(Reuters) July 21, 2016 - Amgen Inc and Allergan Plc said their copycat version of Roche Holding AG's blockbuster cancer treatment, Herceptin, was found as effective as the original in a late-stage study.

FDA Knocks Back Novartis Copy Of Amgen's Drug Neulasta

7/19/2016 11:16 am

(Reuters) July 19, 2016 - U.S. regulators have declined to approve Novartis' so-called biosimilar copy of Amgen's Neulasta drug that fights infections in cancer patients, the Swiss drugmaker said on Tuesday.

FDA Panel Supports Novartis Version of Amgen Arthritis Drug

7/14/2016 11:17 am

(Reuters) July 13, 2016 - Novartis AG's cheaper version of Amgen Inc's arthritis drug Enbrel is highly similar in potency and safety to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan

7/14/2016 10:56 am

(Amgen) July 13, 2016 - Amgen and Daiichi Sankyo Company, Limited today announced the execution of an exclusive agreement to commercialize nine biosimilars in Japan. The deal includes several biosimilars in late-stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab.

Novartis Copy Of Amgen Arthritis Drug Highly Similar: FDA Staff

7/11/2016 10:45 am

(Reuters) July 11, 2016 - Novartis AG's cheaper version of Amgen Inc's blockbuster arthritis drug Enbrel is highly similar in potency and safety to the original, according to a review by Food and Drug Administration staff.

FDA Staff Say Amgen Biosimilar "Highly Similar" to Abbvie's Humira

7/8/2016 11:25 am

(Reuters) July 8, 2016 - Amgen Inc's biosimilar form of AbbVie Inc's arthritis drug Humira, the world's top-selling medicine, is similarly potent and safe as the original product, according to a preliminary review by staff members of the U.S. Food and Drug Administration.

EU Expands Label Of Amgen’s Kyprolis

7/5/2016 10:47 am

(PharmaTimes [UK]) July 5, 2016 - European regulators have cleared the use of Amgen's Kyprolis in combination with just dexamethasone to treat certain adults with multiple myeloma.

European Commission Approves Extended Indication For Amgen's Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients

7/5/2016 07:17 am

(Amgen) July 3, 2016 - Head-to-head phase 3 trial demonstrated superiority of Kyprolis and dexamethasone over Velcade® (bortezomib) and dexamethasone in patients with relapsed multiple myeloma; new indication allows Kyprolis to be used in combination with dexamethasone alone for appropriate patients.

Takeda Revises Collaboration Agreement with Amgen, Returning the Development and Commercialization Rights of Molecules / Products for Japan

6/27/2016 11:50 am

(Takeda) June 24, 2016 - Rights for molecules / products including AMG403 and AMG386 will be returned to Amgen, effective immediately.

Blincyto Improves Overall Survival In B-Cell Precursor Acute Lymphoblastic Leukaemia

6/10/2016 11:05 am

(European Pharmaceutical Review) June 10, 2016 - Amgen has announced new data from a prespecified interim analysis of the Phase III TOWER study, in which Blincyto (blinatumomab) demonstrated an almost two-times increase in median overall survival (OS) compared to standard of care (SOC) in patients with B-cell precursor acute lymphoblastic leukaemia.

Amgen Releases Positive Data For Chronic-Migraine Prevention Drug

6/9/2016 11:35 am

(CNBC) June 9, 2016 - Amgen said Wednesday that it has seen positive results for erenumab (aka AMG 334), the chronic-migraine prevention drug it has been developing with Novartis.

Amgen Announces Launch Of KYPROLIS® (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers

6/4/2016 05:45 pm

(NASDAQ) June 3, 2016 - Amgen today announced the launch of KYPROLIS CENTRAL, an online media resource about the impact of living with relapsed or refractory multiple myeloma.

Investigational Immunotherapy Drug Shrinks Tumors In High-Risk Neuroblastoma Patients

6/3/2016 01:01 pm

(St. Jude Children's) June 3, 2016 - St. Jude Children’s Research Hospital investigators report promising preliminary results at the annual meeting of ASCO for an experimental monoclonal antibody when combined with chemotherapy for newly diagnosed patients.

Scientists Identify New Drivers of Rare Cancer Type

5/31/2016 11:02 am

(University of Würzburg [Germany]) May 30, 2016 - Cancer researchers have identified new genetic drivers of adrenal cancer by performing a comprehensive genomic analysis as part of the "Cancer Genome Atlas Research Network.”

Op-Ed: Obama's Pointless Cancer 'Moonshot'

5/27/2016 10:03 am

(New York Times) May 27, 2016 - It's a Catch-22: The longer we live, the more people will get the disease.

Financial Crisis Caused 500,000 Extra Cancer Deaths, According to Lancet Study

5/26/2016 06:04 am

(The Telegraph/Agence France-Presse [UK]) May 26, 2016 - The global financial crisis may have caused an additional 500,000 cancer deaths from 2008 to 2010, according to a new study, with patients locked out of treatment because of unemployment and healthcare cuts.

CancerCare® Announces First-Ever Acute Myeloid Leukemia Awareness Month in June

5/25/2016 11:03 am

(CancerCare) May 25, 2016 - CancerCare today announced the launch of the first-ever Acute Myeloid Leukemia Awareness Month to be held in June. The goal of the campaign is to put a spotlight on the disease, a rare and difficult-to-treat blood cancer that typically affects older adults.

Agios, Celgene Jump into Immuno-Oncology in Revamped Alliance

5/18/2016 12:04 pm

(Xconomy Boston) May 17, 2016 - Agios Pharmaceuticals rode a wide-ranging partnership with Celgene to a big IPO a few years ago. Today the two companies are partnering once again in a deal that will see Agios try its hand at the increasingly competitive field of cancer immunotherapy.

Study Links Sleep Duration and Frequent Snoring to Poorer Breast Cancer Survival

5/6/2016 11:04 am

(American Academy of Sleep Medicine) May 5, 2016 - A new study reports that short sleep duration combined with frequent snoring reported prior to cancer diagnosis may influence subsequent breast cancer survival.

FDA Panel Urges Mandatory Opioid Training for Doctors

5/5/2016 11:05 am

(Wall Street Journal) May 4, 2016 - An advisory panel to the Food and Drug Administration overwhelmingly endorsed mandatory training for doctors who prescribe opioid painkillers, in an effort to stem what has become a national epidemic of deaths and addiction from the drugs.

SELLAS Life Sciences Announces Positive WT1 Cancer Vaccine (galinpepimut-S) Clinical Results at the 13th International Conference of the International Mesothelioma Interest Group (iMig)

5/5/2016 11:01 am

(Morningstar) May 4, 2016 - SELLAS Life Sciences Group today announced that results from a Phase 2 trial of the Company's WT1 cancer vaccine in patients with malignant pleural mesothelioma (MPM) were presented at the plenary session of the iMig 2016 Conference, being held May 1-4, 2016, in Birmingham, UK.

Gut Bacteria May Predict Risk Of Life-Threatening Infections Following Chemotherapy

5/2/2016 11:01 am

(Discover/University of Minnesota) Apr 28, 2016 - A new study led by researchers at the University of Minnesota and Nantes University Hospital in France shows that the bacteria in people’s gut may predict their risk of life-threatening blood infections following high-dose chemotherapy.

Stigma Keeps Some Cancer Patients From Getting Palliative Care

4/19/2016 01:05 pm

(Reuters) Apr 18, 2016 - Some cancer patients may turn down care that could ease their pain and improve their quality of life because they think this type of “palliative” treatment amounts to giving up and simply waiting to die, a small Canadian study suggests.

Triphase Accelerator Corporation Announces Positive Interim Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma

4/19/2016 01:04 pm

(PM360) Apr 19, 2016 - Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced positive results from its ongoing Phase 1 proof-of-concept study evaluating marizomib in combination with bevacizumab in patients with WHO grade IV malignant glioma.

ELCC 2016 News: Comprehensive Molecular Profiling Shows Disparity Between Primary NSCLC Tumours and Metastases

4/15/2016 11:00 am

(ESMO) Apr 15, 2016 - Important differences of up to 47% in the expression rates of biomarkers between the primary tumour and metastatic sites were detected using comprehensive molecular profiling of non-small-cell lung cancer (NSCLC) samples.

UCLA Scientists Pioneer New Method to Identify Brain Cancer Patients Most Likely to Benefit From Immunotherapy

4/5/2016 11:01 am

(UCLA/Jonsson CCC) Apr 4, 2016 - UCLA researchers have developed a promising method to assess how changes in the immune response can help predict the effectiveness of a new immunotherapy in people with glioblastoma (GBM), the most common and deadly type of brain cancer.

Imbruvica Resistance Points to Poor MCL Outcomes

4/5/2016 11:01 am

(MedPage Today/The Gupta Guide) Apr 4, 2016 - Mantle cell lymphoma (MCL) patients who developed primary or acquired resistance to ibrutinib (Imbruvica) had poor clinical outcomes and no other post-ibrutinib chemotherapy appeared to offer much in the way of salvage, based on an international study.

CMS Issues Oncology Care Model Notices Of Acceptance; COA Comments

4/1/2016 11:01 am

(COA) Apr 1, 2016 - From InsideHealthPolicy.com… CMS this week issued Oncology Care Model notices to practices accepted to that demonstration, industry sources said.

Italian Hospital Begins Using 3D Printed Prosthetic Bone Implants on Cancer Patients

3/30/2016 11:05 am

(InternetMedicine.com) Mar 29, 2016 - Recently, Italy’s National Institute of Rome Tumori Regina Elena, the country’s top cancer surgical center, became the first hospital in the nation to use customized titanium implants to repair bones damaged by bone cancer.

Bernie Sanders' Bad Medicine for Drug Prices

3/30/2016 11:04 am

(Bloomberg Gadfly) Mar 30, 2016 - Bernie Sanders is worrying millionaires, billionaires and now drug patent holders.

Cigarettes Cheaper than E-cigarettes in 44 of 45 Countries Studied

3/28/2016 12:00 pm

(ACS) Mar 28, 2016 - First study to compare costs of cigarettes to e-cigarettes.

Patients With Terminal Cancer Live Longer When Cared For At Home

3/28/2016 11:03 am

(STAT) Mar 28, 2016 - A new study shows that patients with terminal cancer tend to live longer when they choose to die at home instead of in the hospital.

One Man’s Desperate Quest For A Brutal Surgery

3/24/2016 11:01 am

(STAT) Mar 24, 2016 - The operation is so terrifying some call it MOAS: the Mother of All Surgeries. It can take 16 hours. The risk of complications is high. And after 30 years of research, doctors are still arguing about how well it works.

Back to the Essence of Medical Treatment in Oncology

3/22/2016 12:00 pm

(ESMO) Mar 21, 2016 - The latest article to appear on ESMO Open highlights ESMO's hope that the 2015 WHO Model List of Essential Medicines (EML) will empower oncologists and advocates to demand routine availability of the medicines considered essential to guarantee quality care of cancer patients.

Androgen Suppression Plus RT Improves DFS in Prostate Ca

3/17/2016 11:01 am

(MedPage Today/The Gupta Guide) Mar 16, 2016 - Adding 6 months of androgen suppression (AS) to radiation therapy improved biochemical disease-free survival in high-risk localized prostate cancer patients – even at radiation doses of 78 Gy – and it did so with acceptable adverse effects, according to a study reported in the Journal of Clinical Oncology.

UK Cost Agency Rejects Amgen's Virus-Based Cancer Drug

3/16/2016 12:04 pm

(Reuters) Mar 16, 2016 - A first-in-class melanoma drug from Amgen based on a tumor-killing virus has been deemed not worth using on Britain's state health service by the country's cost-effectiveness agency NICE.